Usage: ENTYVIO is indicated for adults with moderately to severely active ulcerative colitis (UC) and moderately to severely active Crohn's disease (CD).
tysabri
(natalizumab)
Biogen Inc.
Usage: TYSABRI is indicated for the treatment of relapsing forms of multiple sclerosis in adults and for inducing and maintaining clinical response in adults with moderately to severely active Crohn's disease, who have not adequately responded to or cannot tolerate conventional therapies. Risks should be carefully considered.